Overview

Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma

Status:
Not yet recruiting
Trial end date:
2033-04-30
Target enrollment:
Participant gender:
Summary
A Phase Ib/III, Multicenter, double-blinded study of Parsaclisib, a PI3Kδ Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma
Phase:
Phase 1
Details
Lead Sponsor:
Innovent Biologics (Suzhou) Co. Ltd.
Treatments:
Lenalidomide
Rituximab